Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020

20 Apr 2021

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Health Systems, Economic Evaluations, Quality of Life
Share to PARP inhibition in cancer therapy

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 33862157
DOI: 10.1016/j.annonc.2021.04.003

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020PMID 33862157Read ↗

Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven OncologySemantic proximity Read ↗

Estimation of US Patients with Cancer who may Respond to Cytotoxic ChemotherapySemantic proximity Read ↗

Evolving or Immutable - Phase I Solid Tumor Trials in the Era of Precision OncologySemantic proximity Read ↗

Assessment of anticancer drug utilization pattern and patients’ survival—A single center experience from Saudi ArabiaSemantic proximity Read ↗

Anticancer Drug Utilization and Prescription Practices in a Saudi Cancer Center (2014-2022)Semantic proximity Read ↗

Global Inequities in Precision Oncology Drug Development: A Cross-Sectional Analysis of FDA Approvals Between 2017-2024Semantic proximity Read ↗

Oncologist-Led, Survivorship-Focused Primary Care: Feasibility and Outcomes of a Novel Integrated Care ModelSemantic proximity Read ↗

Prior authorization for FDA-approved PARP inhibitors in ovarian cancerSemantic proximity Read ↗

Title Page: Oncologist-Led, Survivorship-Focused Primary Care: Feasibility and Outcomes of a Novel Integrated Care ModelSemantic proximity Read ↗

Perspectives of Cancer Patients and Their Health during the COVID-19 PandemicSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.